Cancer Vaccines

Carrington Subsidiary DelSite and ElSohly Laboratories Sign Amendment to Technology License Agreement

Published in Vaccine Weekly, October 10th, 2007

Carrington Laboratories, Inc. (Pink Sheets: CARN) announced its wholly-owned subsidiary DelSite Biotechnologies, Inc. has amended its technology license agreement with privately-held ElSohly Laboratories, Inc. (ELi), of Oxford, Mississippi, for use of GelSite(R) polymer drug delivery.

Both DelSite Biotechnologies and ElSohly Laboratories have been beneficiaries in Cooperative Research and Development Agreements (CRADAs) with the National Cancer Institute (NCI). DelSite's CRADA currently covers the development of a nasal powder vaccine for Human Papillomavirus (HPV). ElSohly's CRADA covered an anticancer drug that has demonstrated anticancer activity and reduction of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2007-10-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry